283 related articles for article (PubMed ID: 17288695)
1. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
Shah M; Butler M; Bramley T; Curtice TG; Fine S
Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
[TBL] [Abstract][Full Text] [Related]
2. Economic costs of benign prostatic hyperplasia in the private sector.
Saigal CS; Joyce G
J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease.
Dalal AA; Shah M; Lunacsek O; Hanania NA
Respir Med; 2011 Oct; 105(10):1516-22. PubMed ID: 21684731
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
[TBL] [Abstract][Full Text] [Related]
5. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.
Black L; Naslund MJ; Gilbert TD; Davis EA; Ollendorf DA
Am J Manag Care; 2006 Mar; 12(4 Suppl):S99-S110. PubMed ID: 16551208
[TBL] [Abstract][Full Text] [Related]
6. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
7. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
Joyce AT; Smith P; Khandker R; Melin JM; Singh A
J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
[TBL] [Abstract][Full Text] [Related]
8. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy.
Fillit H; Hill JW; Futterman R
Fam Med; 2002; 34(7):528-35. PubMed ID: 12144008
[TBL] [Abstract][Full Text] [Related]
9. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS; Yawn BP
Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
[TBL] [Abstract][Full Text] [Related]
10. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care.
Stensland MD; Jacobson JG; Nyhuis A
J Affect Disord; 2007 Aug; 101(1-3):187-93. PubMed ID: 17254637
[TBL] [Abstract][Full Text] [Related]
11. Current practice and resource utilisation in men diagnosed with premature ejaculation.
Nuyts GD; Hill K; Jones MP
Int J Clin Pract; 2008 Oct; 62(10):1533-40. PubMed ID: 18822023
[TBL] [Abstract][Full Text] [Related]
12. Burden of illness of hepatitis C from a managed care organization perspective.
Armstrong EP; Charland SL
Curr Med Res Opin; 2004 May; 20(5):671-9. PubMed ID: 15140332
[TBL] [Abstract][Full Text] [Related]
13. Urologic diseases in America project: benign prostatic hyperplasia.
Wei JT; Calhoun E; Jacobsen SJ
J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
[TBL] [Abstract][Full Text] [Related]
14. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
[TBL] [Abstract][Full Text] [Related]
15. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
[TBL] [Abstract][Full Text] [Related]
16. New insights into the epidemiology and natural history of benign prostatic hyperplasia.
Boyle P
Prog Clin Biol Res; 1994; 386():3-18. PubMed ID: 7528398
[TBL] [Abstract][Full Text] [Related]
17. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting.
Ritzwoller DP; Ellis JL; Korner EJ; Hartsfield CL; Sadosky A
Curr Med Res Opin; 2009 Jun; 25(6):1319-28. PubMed ID: 19419344
[TBL] [Abstract][Full Text] [Related]
18. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension.
Boyle P; Napalkov P
Scand J Urol Nephrol Suppl; 1995; 168():7-12. PubMed ID: 7541551
[TBL] [Abstract][Full Text] [Related]
19. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
[TBL] [Abstract][Full Text] [Related]
20. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
